Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Actinium-225 (225Ac)-Lintuzumab in Older Patients with Previously Untreated Acute Myeloid Leukemia (AML)

Next Previous
X
Search
Trial Profile

Actinium-225 (225Ac)-Lintuzumab in Older Patients with Previously Untreated Acute Myeloid Leukemia (AML)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lintuzumab Ac-225 (Primary) ; Plerixafor; Spironolactone
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use

    • Most Recent Events

    • 26 Mar 2019 According to an Actinium Pharmaceuticals media release, data from this study will be presented at the 11th Targeted-Alpha-Therapy International Symposium (TAT) (Apr 2019).
    • 04 Dec 2018 Preliminary data of the interim analysis (n=18) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 03 Dec 2018 Results from the second cohort of the patients (n=27) presented in a media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top